RA, Atlas-backed biotech spins up with $110M in pursuit of protein degradation via molecular glues

Paul Schloesser

Associate Editor

RA Capital Management has backed more than just one biotech in the protein degradation space, with the hope of changing the way companies can go after so-called “undruggable” targets. In the fall, it backed Avilar Therapeutics and two months ago, it helped pour $102 million into Plexium, the startup headed by Astellas vet Percival Barretto-Ko.

And now, the most recent company to form with RA’s investment, Triana Biomedicines, is out. Armed with a $110 million Series A, the Waltham, MA biotech is looking to go after protein degradation strictly through molecular glues, according to CEO Patrick Trojer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

RA, Atlas-backed biotech spins up with $110M in pursuit of protein degradation via molecular glues

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

RA, At­las-backed biotech spins up with $110M in pur­suit of pro­tein degra­da­tion via mol­e­c­u­lar glues

Paul Schloesser

Associate Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

RA, Atlas-backed biotech spins up with $110M in pursuit of protein degradation via molecular glues

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa